Have any questions?
+44 1234 567 890
Guidelines for Eosinophilic Esophagitis Patient Monitoring in Routine Clinical Practice: Insights from Global Experts
Discover the expert-recommended strategies for monitoring patients with eosinophilic esophagitis (EoE). Delve into the why, how, and when of EoE patient monitoring, supported by rigorous consensus and clinical evidence. Uncover insights from 18 seasoned EoE specialists, paving the way for effective maintenance treatment, complication prevention, and personalized care.
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
Over the last decade, clinical experiences and research studies raised concerns regarding use of proton pump inhibitors (PPIs) as part of the diagnostic strategy for eosinophilic esophagitis (EoE). We aimed to clarify the use of PPIs in the evaluation and treatment of children and adults with suspected EoE to develop updated international consensus criteria for EoE diagnosis.
Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia: An Entity Challenging Current Diagnostic Criteria for Eosinophilic Oesophagitis
Consensus diagnostic recommendations to distinguish gastro-oesophageal reflux disease (GORD) from eosinophilic oesophagitis (EoE) by response to a trial of proton pump inhibitors (PPI) unexpectedly uncovered an entity called “PPI-responsive oesophageal eosinophilia” (PPI-REE).
Emotional Journey of Patients with Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a chronic disease with a rising prevalence. Most adult EoE patients experience difficulties eating solid food and therefore they often avoid having meals with friends and family...
Read more … Emotional Journey of Patients with Eosinophilic Esophagitis
Tolerance to sterilised cow's milk in patients with eosinophilic oesophagitis triggered by milk
Cow's milk protein is the main food trigger for eosinophilic oesophagitis (EoE) in children and adults and should be continuously avoided once identified as such...
Fluticasone Propionate Orally Disintegrating Tablet to Treat EoE: Published results from the Phase 2 FLUTE Trial
APT-1011 is an oral disintegrating tablet (ODT) formulation of fluticasone propionate developed by Ellodi/Adare Pharmaceuticals and designed to disintegrate after put on the tongue without water...